A trend in responses toward “neutral-important” was reported for poor tumour differentiation, primary tumour lymph node status, short time from resection of primary to development of CRPM, primary rectal cancer (vs. colon cancer), abdominal wall involvement, molecular marker status (MSI/KRAS/BRAF) and raised tumour markers (CEA, CA19.9, CA125). This evidence concerns the gene KRAS and rectal cancer.